Thermo Fisher Scientific Acquires Novasep's Henogen Expanded Global Capacity Addresses Growing Demand for Cell and Gene Therapy
15 Jan 2021
The business will be part of the Pharma Services business within the Laboratory Products and Services Segment.
Sanofi to Acquire Kymab, Adding KY1005 to Its Pipeline, a Human Monoclonal Antibody Targeting Key Immune System Regulator OX40L
11 Jan 2021
Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics.
Novartis Builds on Commitment to Addressing Need in Neuropsychiatric Disorders with Cadent Therapeutics Acquisition
17 Dec 2020
Basel, December 17, 2020 — Novartis has entered an agreement to acquire Cadent Therapeutics, a Cambridge, Massachusetts based neuroscience company
Lilly Announces Agreement to Acquire Prevail Therapeutics
15 Dec 2020
Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of approximately $1.040 billion). The CVR is payable (subject to certain terms and conditions) upon the first regulatory approval of a product from Prevail's pipeline as set forth in more detail below. Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases.
Exscientia Receives $4.2M Grant from Bill & Melinda Gates Foundation to Identify New Targets and Leads for Malaria, Tuberculosis, and Non-hormonal Contraception
10 Dec 2020
DyNAbind and Salipro Biotech Enter Collaboration Agreement
9 Dec 2020
DyNAbind GmbH and Salipro Biotech AB are teaming up to tackle drug discovery against challenging membrane protein targets!
Merck to Acquire OncoImmune
23 Nov 2020
"Meaningful new therapeutic options are desperately needed for possibly millions of people around the world who will develop severe or critical COVID-19 disease," said Dr. Roger M. Perlmutter, President Merck Research Laboratories.
Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company's Leading Cardiovascular Franchise
17 Nov 2020
NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc
Calliditas Closes Acquisition of a Controlling Interest in Genkyotex SA
3 Nov 2020
Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX – CALTX; NASDAQ – CALT) today announced the closing of the acquisition of 62.7% of Genkyotex SA ("Genkyotex") (Euronext Paris & Brussels: FR0013399474 – GKTX) in an off-market transaction.
Novartis Announces Collaboration with Molecular Partners to Develop Two DARPin® Therapies Designed for Potential Use Against COVID-19
28 Oct 2020
Basel, October 28, 2020 — Novartis and Molecular Partners AG today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners' anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423.
Join Our Newsletter for Free
